HK1032533A1 - Renal cell carcinoma treatment. - Google Patents
Renal cell carcinoma treatment.Info
- Publication number
- HK1032533A1 HK1032533A1 HK01102198A HK01102198A HK1032533A1 HK 1032533 A1 HK1032533 A1 HK 1032533A1 HK 01102198 A HK01102198 A HK 01102198A HK 01102198 A HK01102198 A HK 01102198A HK 1032533 A1 HK1032533 A1 HK 1032533A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cell carcinoma
- renal cell
- carcinoma treatment
- treatment
- renal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28835999A | 1999-04-08 | 1999-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1032533A1 true HK1032533A1 (en) | 2001-07-27 |
Family
ID=23106761
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK01102198A HK1032533A1 (en) | 1999-04-08 | 2001-03-26 | Renal cell carcinoma treatment. |
HK05109749.0A HK1075417A1 (en) | 1999-04-08 | 2005-11-02 | Renal cell carcinoma treatment |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05109749.0A HK1075417A1 (en) | 1999-04-08 | 2005-11-02 | Renal cell carcinoma treatment |
Country Status (24)
Country | Link |
---|---|
EP (2) | EP1535623B1 (xx) |
JP (2) | JP3712914B2 (xx) |
CN (1) | CN1367702A (xx) |
AR (1) | AR029160A1 (xx) |
AT (2) | ATE296638T1 (xx) |
AU (2) | AU777406B2 (xx) |
BR (1) | BR0009644A (xx) |
CA (1) | CA2303752A1 (xx) |
CO (1) | CO5170412A1 (xx) |
CY (1) | CY1108919T1 (xx) |
DE (2) | DE60020442T2 (xx) |
DK (2) | DK1043025T3 (xx) |
ES (2) | ES2319777T3 (xx) |
HK (2) | HK1032533A1 (xx) |
HU (1) | HU230271B1 (xx) |
MX (1) | MXPA00003401A (xx) |
MY (1) | MY155221A (xx) |
NO (1) | NO328983B1 (xx) |
NZ (1) | NZ514629A (xx) |
PE (1) | PE20010026A1 (xx) |
PT (2) | PT1535623E (xx) |
TW (2) | TW200526243A (xx) |
WO (1) | WO2000061174A2 (xx) |
ZA (1) | ZA200108169B (xx) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU230271B1 (hu) * | 1999-04-08 | 2015-11-30 | Merck Sharp & Dohme Corp | Pegilezett alfa-interferon alkalmazása vesesejt-karcinóma kezelésére |
CA2648077A1 (en) * | 2006-03-31 | 2007-11-08 | Schering Corporation | Parenteral low dose type 1 interferons for bladder cancer |
TW200901989A (en) * | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
US8053430B2 (en) | 2008-10-06 | 2011-11-08 | Haraldsson Boerje | Treatment of renal cell carcinoma |
ES2891564T3 (es) | 2010-04-01 | 2022-01-28 | Oncorena Ab | Tratamiento mejorado del carcinoma de células renales |
CN103463623B (zh) * | 2013-09-03 | 2015-09-09 | 长春海伯尔生物技术有限责任公司 | 一种聚乙二醇干扰素注射液及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5766582A (en) * | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
AU754002B2 (en) * | 1998-03-26 | 2002-10-31 | Merck Sharp & Dohme Corp. | Formulations for protection of peg-interferon alpha conjugates |
HU230271B1 (hu) * | 1999-04-08 | 2015-11-30 | Merck Sharp & Dohme Corp | Pegilezett alfa-interferon alkalmazása vesesejt-karcinóma kezelésére |
-
2000
- 2000-04-06 HU HU0200781A patent/HU230271B1/hu not_active IP Right Cessation
- 2000-04-06 DE DE60020442T patent/DE60020442T2/de not_active Expired - Lifetime
- 2000-04-06 MX MXPA00003401A patent/MXPA00003401A/es active IP Right Grant
- 2000-04-06 DK DK00107100T patent/DK1043025T3/da active
- 2000-04-06 NZ NZ514629A patent/NZ514629A/xx not_active IP Right Cessation
- 2000-04-06 EP EP05002952A patent/EP1535623B1/en not_active Expired - Lifetime
- 2000-04-06 PT PT05002952T patent/PT1535623E/pt unknown
- 2000-04-06 WO PCT/US2000/009127 patent/WO2000061174A2/en active Application Filing
- 2000-04-06 DE DE60041291T patent/DE60041291D1/de not_active Expired - Lifetime
- 2000-04-06 BR BR0009644-0A patent/BR0009644A/pt not_active Application Discontinuation
- 2000-04-06 EP EP00107100A patent/EP1043025B1/en not_active Expired - Lifetime
- 2000-04-06 TW TW094103729A patent/TW200526243A/zh unknown
- 2000-04-06 PT PT00107100T patent/PT1043025E/pt unknown
- 2000-04-06 DK DK05002952T patent/DK1535623T3/da active
- 2000-04-06 AT AT00107100T patent/ATE296638T1/de active
- 2000-04-06 CN CN00808740A patent/CN1367702A/zh active Pending
- 2000-04-06 JP JP2000105528A patent/JP3712914B2/ja not_active Expired - Fee Related
- 2000-04-06 ES ES05002952T patent/ES2319777T3/es not_active Expired - Lifetime
- 2000-04-06 CO CO00025239A patent/CO5170412A1/es not_active Application Discontinuation
- 2000-04-06 TW TW089106326A patent/TWI310314B/zh not_active IP Right Cessation
- 2000-04-06 ES ES00107100T patent/ES2239953T3/es not_active Expired - Lifetime
- 2000-04-06 JP JP2000105531A patent/JP4721488B2/ja not_active Expired - Fee Related
- 2000-04-06 AU AU42044/00A patent/AU777406B2/en not_active Ceased
- 2000-04-06 AR ARP000101572A patent/AR029160A1/es unknown
- 2000-04-06 CA CA002303752A patent/CA2303752A1/en not_active Abandoned
- 2000-04-06 AT AT05002952T patent/ATE419002T1/de active
- 2000-04-07 MY MYPI20001452A patent/MY155221A/en unknown
- 2000-04-07 PE PE2000000316A patent/PE20010026A1/es not_active Application Discontinuation
-
2001
- 2001-03-26 HK HK01102198A patent/HK1032533A1/xx not_active IP Right Cessation
- 2001-10-04 ZA ZA200108169A patent/ZA200108169B/en unknown
- 2001-10-05 NO NO20014851A patent/NO328983B1/no not_active IP Right Cessation
-
2004
- 2004-12-23 AU AU2004242454A patent/AU2004242454B2/en not_active Ceased
-
2005
- 2005-11-02 HK HK05109749.0A patent/HK1075417A1/xx not_active IP Right Cessation
-
2009
- 2009-03-24 CY CY20091100350T patent/CY1108919T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA01013362A (es) | Anticuerpos de humano, anti-alfavbeta3 recombinantes, °cidos nucleicos que codifican a los mismos y metodos de uso. | |
EG24361A (en) | 4-pyrimiding1-n-acy1.l.phenlalanines | |
ZA200200477B (en) | 2-pyrazolin-5-ones. | |
ZA200202537B (en) | Pour-on-formulations. | |
ZA993345B (en) | Nefazodone dosage form. | |
ZA200201829B (en) | New phenylpiperazines. | |
HK1053470A1 (en) | 4-Pyridinyln-acyl-l-phenylalanines. | |
HK1029502A1 (en) | Slider-pull-assembling unit. | |
ZA200203177B (en) | Regeneration. | |
HK1075417A1 (en) | Renal cell carcinoma treatment | |
ZA200105690B (en) | Novel treatment. | |
MXPA02000261A (es) | Aminoindanos novedosos. | |
GB0029278D0 (en) | I.S. Machine | |
GB0029720D0 (en) | I.S machine7544232001 | |
HK1032679A1 (en) | Connector. | |
GB0005000D0 (en) | I.S. machine | |
ZA200204581B (en) | Nitro-sulfobenzamides. | |
HK1031254A1 (en) | Tachogragh. | |
GB2347419B (en) | I.S. machine | |
ZA200005361B (en) | Positioning arrangement. | |
GB0005001D0 (en) | I.S. machine | |
ZA200004791B (en) | Filter. | |
ZA200001002B (en) | Inclusion complex. | |
ZA200007026B (en) | Acart. | |
ZA200007821B (en) | Hidroponiese Plantproduksiestelsel. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20170406 |